Igniting an agenda for health promotion for women: critical perspectives, evidence-based practice, and innovative knowledge translation.

Health promotion is a set of strategies for positively influencing health through a range of individual, community-based, and population interventions. Despite international recognition that gender is a primary determinant of health and that gender roles can negatively affect health, the health promotion field has not yet articulated how to integrate gender theoretically or practically into its vision. For example, interventions often fail to critically consider women's or men's diverse social locations, gender-based power relations, or sex-based differences in health status. Yet without such analyses, interventions can result in the accommodation or exploitation of gender relations that disadvantage women and compromise their health. In this paper, we seek to ignite an agenda for health promotion for women. We discuss the need for a conceptual framework that includes a sex-gender-diversity analysis and critically considers 'what counts' as health promotion to guide the development and implementation of evidence-based practice. We also consider how innovative knowledge translation practices, technology developments and action research can advance this agenda in ways that foster the participation of a wide range of stakeholders.

Reflecting the changing face of chronic obstructive pulmonary disease: sex and gender in public education materials on COPD.

Emerging evidence suggests that sex and gender differences exist in the prevalence, susceptibility to, severity of, and response to treatment and management of, chronic obstructive pulmonary disease (COPD). However, the identification of knowledge gaps regarding sex, gender, and COPD involves not only pinpointing what areas of etiology, epidemiology, and management need to be examined from a sex and gender perspective (as discussed in other articles of this issue), but also must include discussion of how such new and emerging findings are translated to health care professionals, policy makers, and the general population. How emerging knowledge is reflected in educational, awareness-raising, and policy materials made available to the public through community-based organizations, lung health advocacy organizations, the government, and clinicians is not known. A preliminary examination of such documents from around the world suggests that many materials continue to present COPD as a disease that primarily afflicts men. This gap in the translation of research knowledge may be specifically problematic for women-for example, because they may not be adequately informed of the symptoms of COPD, be appropriately screened for the disease, or receive appropriate interventions and treatment.

Noise-induced sleep maintenance insomnia: hypnotic and residual effects of zaleplon.

AIMS: The primary objective of the study was to assess the residual effects of zaleplon in the morning, 4 h after a middle-of-the-night administration. The secondary objective was to investigate the effectiveness of zaleplon in promoting sleep in healthy volunteers with noise-induced sleep maintenance insomnia. METHODS: Thirteen healthy male and female volunteers (aged 20-30 years) with normal hearing, who were sensitive to the sleep-disrupting effects of noise, participated in a double-blind, placebo- and active-drug controlled, four-period cross-over study. The subjects were permitted to sleep for 5 h (22.45-03.45 h) in a quiet environment before they were awoken. At 04.00 h they ingested 10 mg zaleplon, 20 mg zaleplon, 7.5 mg zopiclone (active control), or placebo before a second period of sleep (04.00-08.00 h), during which they were exposed to an 80 dB(A) 1 kHz pure tone pulse with an inter-tone interval of 1 s and a duration of 50 ms. The sound stimulus was stopped after 10 min of persistent sleep or after 2 h if the subject had not fallen asleep. Residual effects were assessed at 08.00 h (4 h after drug administration) using the digit symbol substitution test (DSST), choice reaction time (CRT), critical flicker fusion (CFF), and immediate and delayed free recall of a 20 word list. The data were analysed by analysis of variance. A Bonferroni adjustment was made for the three active treatments compared with placebo. RESULTS: There were no residual effects of zaleplon (10 and 20 mg) compared with placebo. Zopiclone impaired memory by delaying the free recall of words (P = 0.001) and attenuated performance on DSST (P = 0.004) and CRT (P = 0.001), compared with placebo. Zaleplon reduced the latency to persistent sleep (10 mg, P = 0.001; 20 mg, P = 0.014) and the 20 mg dose reduced stage 1 sleep (P = 0.012) compared with placebo. Zopiclone reduced stage 1 sleep (P = 0.001), increased stage 3 sleep (P = 0.0001) and increased total sleep time (P = 0.003), compared with placebo. CONCLUSIONS: Zaleplon (10 mg and 20 mg), administered in the middle of the night 4 h before arising, shortens sleep onset without impairing next-day performance.